Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids—The CASPAR Study
Changes in serial measurements of serum CgA had a favorable specificity and negative predictive value, making this test a useful adjunct to routine radiographic monitoring.
Authors
- Daniel M. Halperin (ORCID: https://orcid.org/0000-0002-3113-930X)
- Qing H. Meng (ORCID: https://orcid.org/0000-0002-1433-9860)
- Katrin Stade
- Henning Jann (ORCID: https://orcid.org/0000-0003-4095-336X)
- Joshua A. Bornhorst (ORCID: https://orcid.org/0009-0003-9297-3271)
- Run‐Zhang Shi (ORCID: https://orcid.org/0000-0003-4917-7942)
- Shagufta Shaheen (ORCID: https://orcid.org/0000-0001-8385-1641)
- Andrej Schwabe
- Þorvarður R. Hálfdánarson (ORCID: https://orcid.org/0000-0001-8460-1257)
Institutions
- Mayo Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- Mayo Clinic in Arizona (US)
- Stanford Medicine (US)
- Mayo Clinic in Florida (US)
- Thermo Fisher Scientific (Germany) (DE)
- Thermo Fisher Scientific (Israel) (IL)
- Charité - Universitätsmedizin Berlin (DE)
- Stanford University (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-1875
- Citations
- 1
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.39